Halozyme Sees 2013 Cash Burn $45-50M, Cash Balance ~$100M

Halozyme Therapeutics, Inc.

, a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care, today announced that the Company ended 2012 with a cash balance of approximately $100 million and expects 2013 net cash burn to be between $45 and $50 million.  The Company also announced it secured a $30 million term loan from Oxford Finance and Silicon Valley Bank.